Get the Stockscreener App
0.7692
3.97%
0.0294
After Hours:
.77
0.0008
+0.10%
Ocugen Inc stock is traded at $0.7692, with a volume of 2.20M.
It is up +3.97% in the last 24 hours and down -4.87% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.7398
Open:
$0.746
24h Volume:
2.20M
Relative Volume:
0.47
Market Cap:
$224.08M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.8489
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-1.37%
1M Performance:
-4.87%
6M Performance:
-47.67%
1Y Performance:
+39.73%
1-Day Range:
$0.731
$0.7765
1-Week Range:
$0.705
$0.8199
52-Week Range:
$0.495
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.7692 | 224.08M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen’s OCU-500 inhaled mucosal vaccine for COVID-19 gains IND clearance - BioWorld Online
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 - GlobeNewswire
FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - StockTitan
Ocugen Stock: Positioned for Growth Amid Biopharma Innovation - The Africa Logistics
Ocugen's (OCGN) Buy Rating Reiterated at Chardan Capital - MarketBeat
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Lawsuits Filed Against OCGN, CRMD and ARDXJakubowitz Law Pursues Shareholders Claims - AccessWire
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? - MSN
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MSN
Breakthrough in Sight? Ocugen's OCU200 Targets Vision Loss for Millions in New Clinical Trial - MyChesCo
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment - MSN
Breakthrough in Vision: Ocugen's OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa - MyChesCo
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema - Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 1 - GlobeNewswire
Ocugen Launches Phase 1 Trial for Novel Eye Disease Treatment OCU200 in Diabetic Patients - StockTitan
Long-term potential revealed for novel modifier gene therapy - Marketscreener.com
Ocugen's (OCGN) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa - Ocugen
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple - GlobeNewswire
Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - StockTitan
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Earnings call transcript: Ocugen Q3 2024 highlights clinical progress By Investing.com - Investing.com Canada
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Earnings call transcript: Ocugen Q3 2024 highlights clinical progress - Investing.com
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MSN
Ocugen’s Gene Therapy Trial for Dry AMD Advances - MSN
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
State Street Corp Increases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - MarketBeat
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Ocugen Inc. stock rises Friday, still underperforms market - MarketWatch
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Data and Safety Monitoring Board Reviews Interim Safety - GlobeNewswire
Ocugen's Eye Treatment Shows Promising Safety Data in Phase 1/2 Trial for Macular Degeneration - StockTitan
Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):